Pyxis Oncology, Inc. (PYXS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 76/100 (CRITICAL), 4.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 12.1% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
- Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
- Pyxis Oncology Announces Proposed Public Offering
- Pyxis Oncology shares fall 7% despite updated MICVO trial results
- Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
- Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
- Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
- Pyxis Oncology to Participate in Upcoming Investor Conferences
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Pyxis Oncology, Inc..
Full PYXS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.